Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib plus low-dose cytarabine versus placebo plus low-dose cytarabine in older untreated acute myeloid leukemia patients ineligible for intensive induction
2012-002487-27Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Volasertib + low-dose cytarabine with Placebo + low-dose cytarabine (2 arms). Primary endpoint: Complete remission and complete remission with incomplete blood count recovery. Started Nov 2012; status: completed.
02
Drugs
volasertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2012-002487-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002487-27.